A parallel-group, multi-centre, active-controlled (glibenclamide) long-term extension study to evaluate the safety and tolerability of oral tesaglitazar therapy in patients with type 2 diabetes

Trial Profile

A parallel-group, multi-centre, active-controlled (glibenclamide) long-term extension study to evaluate the safety and tolerability of oral tesaglitazar therapy in patients with type 2 diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Tesaglitazar (Primary) ; Glibenclamide
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms GALLEX-4
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Dec 2007 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 29 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top